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Abstract
Introduction: Septic-shock-associated acute kidney injury (SSAKI) carries high morbidity in the pediatric population.
Effective treatment strategies are lacking, in part due to poor detection and prediction. There is a need to identify
novel candidate biomarkers of SSAKI. The objective of our study was to determine whether microarray data from
children with septic shock could be used to derive a panel of candidate biomarkers for predicting SSAKI.
Methods: A retrospective cohort study compared microarray data representing the first 24 hours of admission for
179 children with septic shock with those of 53 age-matched normal controls. SSAKI was defined as a >200%
increase of baseline serum creatinine, persistent to 7 days after admission.
Results: Patients with SSAKI (n = 31) and patients without SSAKI (n = 148) were clinically similar, but SSAKI carried
a higher mortality (45% vs. 10%). Twenty-one unique gene probes were upregulated in SSAKI patients versus
patients without SSAKI. Using leave-one-out cross-validation and class prediction modeling, these probes predicted
SSAKI with a sensitivity of 98% (95% confidence interval (CI) = 81 to 100) and a specificity of 80% (95% CI = 72 to
86). Serum protein levels of two specific genes showed high sensitivity for predicting SSAKI: matrix
metalloproteinase-8 (89%, 95% CI = 64 to 98) and elastase-2 (83%, 95% CI = 58 to 96). Both biomarkers carried a
negative predictive value of 95%. When applied to a validation cohort, although both biomarkers carried low
specificity (matrix metalloproteinase-8: 41%, 95% CI = 28 to 50; and elastase-2: 49%, 95% CI = 36 to 62), they
carried high sensitivity (100%, 95% CI = 68 to 100 for both).
Conclusions: Gene probes upregulated in critically ill pediatric patients with septic shock may allow for the
identification of novel candidate serum biomarkers for SSAKI prediction.
Introduction
Septic shock leads to significant morbidity and mortality
in critically ill adult and pediatric patients [1,2]. Mean-
while, acute kidney injury (AKI) is also known to be
independently associated with mortality and morbidity
in critically ill patients. The treatment of sepsis costs the
US population over $15 billion/year for adults and over
$2 billion/year for children, while the costs for AKI
approach $10 billion/year for adults alone [3,4]. Sepsis is
the most common precipitant for AKI in both popula-
tions, and the development of kidney injury in the con-
text of sepsis is a poor prognostic sign. Together the
two disease processes carry up to 75% mortality [5-9].
Effective therapies for septic-shock-associated acute
kidney injury (SSAKI) are lacking. Detection schemes
for SSAKI have been and still are dependent on serum
creatinine, a flawed real-time marker of AKI [10,11].
Diagnoses of SSAKI based upon changes in creatinine,
therefore, are considerably varied and create heterogene-
ity between studies investigating AKI therapy. Biomarker
research seeking to identify more robust markers of AKI
has yielded promising results. Neutrophil gelatinase-
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all demonstrated encouraging efficacy for predicting
ischemic or nephrotoxic AKI and its severity [12-14].
Sepsis intrinsically induces increased expression of some
AKI biomarkers (for example, NGAL), and studies of
NGAL levels in patients with SSAKI often demonstrate
high sensitivity with modest specificity [9,14-17].
Importantly, the pathophysiology of SSAKI may be
unique from that of ischemic or nephrotoxic AKI [18].
Therapies aiming to restore renal perfusion in ischemic
AKI [19-21] have not been demonstrated to be particu-
larly effective and may be even less effective in SSAKI, a
process that may not be secondary to impaired glomeru-
lar preload. Persistent SSAKI may fall into the class of
fluid-unresponsive AKI [22]. Renal replacement therapy
has been used as therapy for AKI and data exist demon-
strating that initiation prior to accumulation of excessive
fluid overload may improve outcomes [23,24]. The
aggregate data, however, show that patients with SSAKI
have consistently increased mortality, even with early
renal replacement therapy initiation [25,26]. The modest
efficacy of biomarkers at identifying SSAKI also under-
scores the notion that the pathophysiology of SSAKI is
unique from other etiologies of AKI. There is a need to
identify novel candidate biomarkers of SSAKI, which
would expedite early treatment aimed at preventing the
effects of this highly morbid complication of sepsis.
We have generated an extensive genome-wide expres-
sion database from children with septic shock by way of
microarray technology and have now leveraged this
database to identify candidate biomarkers for SSAKI
[27-32]. Herein we report the identification of 21 unique
gene probes upregulated in patients with SSAKI, within
the first 24 hours of admission to the pediatric intensive
care unit (PICU), and their ability to robustly predict
SSAKI. Two readily measurable gene products from this
list, matrix metalloproteinase-8 (MMP-8) and neutrophil
elastase-2, show high sensitivity for SSAKI in a cohort
of patients with septic shock.
Materials and methods
Patients and data collection
The study protocol was approved by the Institutional
Review Boards of each participating institution (n =1 1 ) .
Children ≤10 years of age admitted to the PICU and
meeting pediatric-specific criteria for septic shock were
eligible for enrollment [33]. Controls, used to normalize
the microarray data across the patients with septic
shock and to conduct the three-group analysis of var-
iance in the first derivation analysis, were recruited from
the ambulatory departments of participating institutions
using published inclusion and exclusion criteria [28-32].
These controls were required to reliably compare data
across different batches of samples. All patients and
controls in the derivation cohort were previously
reported in microarray-based studies addressing hypoth-
eses entirely different from that of the current report
[28-32]. All microarray data have been deposited in the
NCBI Gene Expression Omnibus (GEO:GSE26440 and
GEO:GSE26378). The patients in the validation cohort
have not been previously reported in any manner.
After informed consent from legal guardians, blood
samples were obtained within 24 hours of initial presen-
tation to the PICU with septic shock. Clinical and
laboratory data were collected daily while in the PICU,
and were stored using a web-based database. Mortality
was tracked for 28 days after enrollment.
SSAKI was defined as a >200% rise of serum creati-
nine relative to the median normal value for age [34,35],
persistent to day 7 of PICU admission. For example, if a
patient had a >200% rise of serum creatinine upon
admission to the PICU but returned to <200% by day 7
(without renal replacement therapy), then that patient
was classified as not having SSAKI. Although stringent,
this definition allowed us to identify those patients with
persistent fluid-unresponsive AKI. No patient in this
study had known pre-existing chronic kidney disease.
Patients who died before day 7 with a creatinine rise
>200% from baseline were included.
RNA extraction and microarray hybridization
T o t a lR N Aw a si s o l a t e df r o mw h o l eb l o o du s i n gt h e
PaxGene™ Blood RNA System (PreAnalytiX, Qiagen/
Becton Dickson, Valencia, CA, USA). Microarray hybri-
dization was performed as previously described using
the Human Genome U133 Plus 2.0 GeneChip (Affyme-
trix, Santa Clara, CA, USA) [27-32].
Serum protein biomarker measurements
Measurements of serum MMP-8 and elastase-2 protein
levels were performed using a Luminex 200 multi-plex
instrument (Luminex Corporation, Austin, TX, USA)
and antibody-coated magnetic beads (Millipore,
Billerica, MA, USA) following the manufacturer’s
specifications.
Data analysis
Analyses were performed using one patient sample per
chip. Image files were captured using an Affymetrix
GeneChip Scanner 3000. CEL files were subsequently
preprocessed using robust multiple-array average nor-
malization and GeneSpring GX 7.3 software (Agilent
Technologies, Palo Alto, CA, USA). All signal intensity-
based data were used after robust multiple-array average
normalization, which specifically suppresses all but sig-
nificant variation among lower intensity probe sets [36].
All chips representing patient samples were then nor-
malized to the respective median values of controls.
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categories were measured using GeneSpring GX 7.3
software, as were the class prediction procedures. Recei-
ver operating characteristic (ROC) curves and calcula-
tions of biomarker performance were performed using
SPSS (IBM Corporation, Somers, NY, USA). Ordinal
and continuous clinical variables not normally distribu-
ted were analyzed via analysis of variance on ranks.
Dichotomous clinical variables were analyzed using a
chi-square test (SigmaStat software; Systat Software,
Inc., San Jose, CA, USA).
Results
Initial derivation of candidate biomarkers for SSAKI
Based on complete microarray data from 179 children
with septic shock, we used a multistage approach to
begin deriving a panel of candidate biomarkers to pre-
dict SSAKI. All of the microarray data in the derivation
process represent the first 24 hours of admission to the
PICU with septic shock. Table 1 provides the clinical
characteristics of the derivation cohort, consisting of
148 patients without SSAKI and 31 patients with SSAKI.
The patients with SSAKI had a higher Pediatric Risk of
Mortality score and a higher mortality rate, compared
with the patients without SSAKI. All other variables
shown in Table 1 were not significantly different
between the two groups.
I nt h ef i r s td e r i v a t i o ns t a g ew ec o n d u c t e dat w o - s t e p
statistical test to determine which gene probes on the
array (>80,000 gene probes) were differentially regulated
between patients with and without SSAKI. In step one
we conducted a three-group analysis of variance using
normal controls (n = 53), patients without SSAKI, and
patients with SSAKI as the comparison groups, and cor-
rections for multiple comparisons (Benjamini-Hochberg
false discovery rate = 5%). This was followed by a post
hoc test (Tukey) to isolate the gene probes differentially
regulated between patients with and without SSAKI
(100 gene probes, see Additional file 1).
The 100-gene probe list presented in Additional file 1
corresponds to 61 unique and well-annotated genes.
Twenty-one of the gene probes were upregulated in the
patients with SSAKI, relative to the patients without
SSAKI (Table 2). These 21 gene probes were subse-
quently used in a leave-one-out cross-validation proce-
dure (Support Vector Machines algorithm) to predict
‘SSAKI’ and ‘no SSAKI’ classes in the derivation cohort.
The leave-one-out cross-validation procedure removes a
single observation from the original sample as validation
- and analyzes the remaining observations as compara-
tors. The procedure is repeated for each observation in
the sample so that each is used once as validation. Fig-
ure 1 provides the 2 × 2 contingency table demonstrat-
ing the results of the leave-one-out cross validation
procedures, and the associated performance calculations.
Figure 1 demonstrates that the expression patterns of
these 21 upregulated gene probes can predict SSAKI
with a high degree of sensitivity and modestly high spe-
cificity in the derivation cohort. In addition, the expres-
sion patterns of these 21 upregulated gene probes have
a high negative predictive value for SSAKI in the deriva-
tion cohort. Accordingly these 21 gene probes represent
potential candidate biomarkers for predicting SSAKI.
Matrix metalloproteinase-8 and elastase-2 serum levels
as predictors of SSAKI
To further test the ability of the gene probes to pre-
dict SSAKI, we conducted initial measurements of
selected gene probe products. Two gene probes corre-
sponding to MMP-8 and one gene probe corresponding
to elastase-2 were included in the 21 gene probes used
in the class prediction modeling procedure described
above. Since MMP-8 and elastase-2 protein levels can
be readily measured in the serum compartment, we
tested the ability of MMP-8 and elastase-2 serum pro-
tein levels to predict SSAKI in the derivation cohort.
There were 150 parallel serum samples from the deriva-
tion cohort available for this analysis (132 patients with-
out SSAKI and 18 patients with SSAKI). Figure 2
demonstrates that both MMP-8 and elastase-2 serum
protein levels were higher in patients with SSAKI, com-
pared with patients without kidney injury, thus corro-
borating the microarray data.
We next constructed ROC curves to determine the
ability of serum protein levels of MMP-8 and elastase-2,
respectively, to predict SSAKI in the derivation cohort
(Figure 3). From these ROC curves we empirically
s e l e c t e dc u t - o f fv a l u e so f1 1n g / m l( M M P - 8 )a n d2 3 5
ng/ml (elastase-2) with an ap r i o r igoal of achieving a
high sensitivity at the expense of specificity. The perfor-
mance characteristics of the respective cut-off values are
shown in Table 3. For both MMP-8 and elastase-2, the
Table 1 Clinical characteristics of the derivation cohort
Characteristic No SSAKI
(n = 148)
SSAKI
(n = 31)
Age (years) 2.4 (1.0 to 6.0) 2.7 (0.8 to 8.4)
Males 87 (59) 22 (71)
Pediatric Risk of Mortality 14 (9 to 19) 22 (16 to 31)*
Deaths
a 15 (10) 14 (45)*
With Gram-negative organism 43 (28) 4 (13)
With Gram-positive organism 37 (25) 10 (32)
With negative cultures
b 57 (39) 14 (45)
Data presented as median (interquartile range) or number (%). Sepsis-shock-
associated acute kidney injury (SSAKI) defined as a persistent >200% increase
of serum creatinine at day 7 of hospitalization.
aTwenty-eight-day mortality.
bRefers to patients in which no pathogenic organism was isolated. The total
percentage of organisms does not add up to 100% because patients with
either a fungal or viral pathogen were not included. *P <0.05 versus patients
without kidney injury.
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with a relatively high sensitivity. In addition, both cut-
off values had a high negative predictive value for the
development of SSAKI. When we incorporated both
MMP-8 and elastase-2 into a multiple regression analy-
sis, we were unable to substantially improve the ability
to predict SSAKI compared with the ability of each can-
didate biomarker alone (data not shown).
Table 2 Gene probes upregulated in patients with kidney injury that predict ‘no SSAKI’ and ‘SSAKI’ classes
Affymetrix ID Fold change Gene symbol GenBank ID Description
202411_at 2.088 IFI27 NM_005532 IFNa-inducible protein 27
207329_at 1.756 MMP8 NM_002424 Matrix metallopeptidase-8
212768_s_at 1.711 OLFM4 AL390736 Olfactomedin 4
219975_x_at 1.697 OLAH NM_018324 Oleoyl-ACP hydrolase
206145_at 1.688 RHAG NM_000324 Rh-associated glycoprotein
231688_at 1.666 MMP8 AW337833 Matrix metallopeptidase-8
233126_s_at 1.664 OLAH AK001844 Oleoyl-ACP hydrolase
211820_x_at 1.612 GYPA U00179 Glycophorin A
222945_x_at 1.612 OLAH AI125696 Oleoyl-ACP hydrolase
220496_at 1.601 CLEC1B NM_016509 C-type lectin domain family 1, member B
219478_at 1.601 WFDC1 NM_021197 WAP four-disulfide core domain 1
205110_s_at 1.551 FGF13 NM_004114 Fibroblast growth factor 13
206871_at 1.525 ELA2 NM_001972 Elastase-2, neutrophil
205612_at 1.522 MMRN1 NM_007351 Multimerin 1
219410_at 1.517 TMEM45A NM_018004 Transmembrane protein 45A
207341_at 1.512 PRTN3 NM_002777 Proteinase 3
218542_at 1.509 CEP55 NM_018131 Centrosomal protein 55 kDa
211372_s_at 1.505 IL1R2 U64094 IL-1 receptor type II
207269_at 1.497 DEFA4 NM_001925 Defensin, a4, corticostatin
201292_at 1.492 TOP2A AL561834 Topoisomerase (DNA) IIa 170 kDa
211821_x_at 1.486 GYPA U00178 Glycophorin A
Twenty-one gene probes upregulated in patients with kidney injury and used for the leave-one-out cross-validation procedure to predict ‘no SSAKI’ and ‘SSAKI’
classes. SSAKI, sepsis-shock-associated acute kidney injury.
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Figure 1 Results of the leave-one-out cross-validation procedure involving 21 gene probes. The procedure was based on a Support
Vector Machines algorithm and was targeted at prediction of ‘SSAKI’ and ‘no SSAKI’ classes. Performance calculations provided as the percentage
with 95% confidence intervals (CIs). LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; SSAKI, sepsis-shock-
associated acute kidney injury.
Basu et al. Critical Care 2011, 15:R273
http://ccforum.com/content/15/6/R273
Page 4 of 11MMP-8
No SSAKI SSAKI
n
g
/
m
l
0
100
200
300
400
500
600
700
800
Elastase-2
No SSAKI SSAKI
n
g
/
m
l
0
500
1000
1500
2000
2500
3000
3500
Figure 2 Serum matrix metalloproteinase-8 and elastase-2 levels in patients with and without sepsis-shock-associated acute kidney
injury. Serum matrix metalloproteinase-8 (MMP-8) and elastase-2 levels are higher in patients with sepsis-shock-associated acute kidney injury
(SSAKI) than patients without SSAKI. Patients with SSAKI (n = 132) were compared with patients without SSAKI (n = 18). Serum samples were
obtained within 24 hours of admission to the pediatric ICU with septic shock and were drawn in parallel with RNA samples. Medians and
interquartile ranges for the targets of interest for no SSAKI versus SSAKI: MMP-8, 26 (9 to 49) versus 40 (20 to 98), P = 0.029; and neutrophil
elastase-2, 340 (9 to 571) and 574 (444 to 911), P = 0.01 (rank-sum test).
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Having demonstrated the individual performances of
MMP-8 and elastase-2 as candidate biomarkers for pre-
dicting SSAKI in the derivation cohort, we next applied
the same respective cut-off values to a separate valida-
tion cohort of patients. The validation cohort consisted
of 59 patients without SSAKI and 11 patients with
SSAKI. The clinical characteristics of the validation
cohort were not significantly different from those of the
derivation cohort, except that in the validation cohort
MMP-8 
Elastase-2 
Figure 3 Matrix metalloproteinase-8 and elastase-2 as candidate biomarkers for predicting sepsis-shock-associated acute kidney
injury. Receiver operating characteristic curves for matrix metalloproteinase-8 (MMP-8) and elastase-2 as candidate biomarkers for predicting
sepsis-shock-associated acute kidney injury. Area under the curve = 0.659 (95% confidence interval = 0.520 to 0.798) and area under the curve =
0.688 (95% confidence interval = 0.549 to 0.826) for matrix MMP-8 and elastase-2, respectively.
Table 3 Individual performance calculations of serum
protein levels for predicting SSAKI in the derivation
cohort
Performance MMP-8 Elastase-2
Sensitivity 89 (64 to 98) 83 (58 to 96)
Specificity 29 (21 to 37) 42 (34 to 51)
Positive predictive value 15 (9 to 23) 16 (10 to 26)
Negative predictive value 95 (82 to 99) 95 (85 to 99)
Data expressed as percentage (95% confidence intervals). MMP-8, matrix
metalloproteinase-8; SSAKI, septic-shock-associated acute kidney injury.
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males and a lower proportion of patients with negative
cultures compared with thep a t i e n t sw i t h o u tS S A K I
(Table 4).
Table 5 provides the respective performance calcula-
tions for the two candidate biomarkers in the validation
cohort. Both candidate biomarkers were able to predict
SSAKI with 100% sensitivity in the validation cohort.
However, the markers carried limited positive predictive
value. In the validation cohort, 35 patients had an
MMP-8 level >11 ng/ml without sustained SSAKI. In
these patients, eight (23%) met criteria for at least mild
AKI (pediatric Risk, Injury, Failure, Loss, End-Stage kid-
ney injury (RIFLE) Risk) for at least 1 day. Also in the
validation cohort, 30 patients had an elastase-2 level
>235 ng/ml without sustained SSAKI. OK Nine (30%) of
these patients met at least pediatric RIFLE Risk criteria
for at least 1 day. Both biomarkers had negative predic-
tive values for SSAKI of 100%, an important finding that
adds clinical utility for practitioners treating patients
who carry risks for developing severe AKI. Collectively,
our results indicate that admission microarray data can
be used to identify novel candidate biomarkers for
SSAKI.
Discussion
We have demonstrated that microarray data can be
leveraged to identify gene expression patterns common
in SSAKI. Although mRNA levels do not necessarily
correlate with protein expression, analysis of MMP-8
and elastase-2 protein levels in the serum compartment
indicates that our gene expression data can identify
novel serum protein biomarkers for SSAKI.
Although sepsis is the most important predictor of
AKI in critically ill patients [37,38], few clinical studies
are dedicated to identifying the early phenotype of
patients with SSAKI. Interrogation of several large data-
bases of critically ill adult patients has yielded variables
that may be predictive of SSAKI but are not consistently
reliable (Table 6). The conclusions of these studies sim-
ply state that elevated proinflammatory markers portend
adverse outcomes in acute kidney disease and death in
patients with septic shock [39,40].
NGAL has received considerable attention as a poten-
tial biomarker for AKI. NGAL derivation and validation
studies were primarily performed in ischemic or nephro-
toxic AKI with great efficacy [13], while investigations of
NGAL biomarker utility in SSAKI have demonstrated
variable results. In the general ICU population, serum
NGAL levels have not been reliably demonstrated to be
s p e c i f i cf o rS S A K I( T a b l e6 ) .W ep r e v i o u s l yp u b l i s h e d
that while day 1 serum NGAL levels were elevated, with
acceptable sensitivity, in children who develop SSAKI,
the specificity was quite poor (39%) [41]. A recent pro-
spective cohort study of 632 adult ICU patients demon-
strated that the likelihood ratio for AKI (RIFLE Failure)
was 1.71 for NGAL, and that elevated NGAL alone con-
ferred an ROC area under curve of 0.77 for RIFLE Fail-
ure but when included in a ‘most efficient clinical
model’ NGAL improved the ROC area under curve for
RIFLE Failure to 0.96 [42]. OK In this study, specificity
was 50% for a plasma NGAL cut-off value of 168 ng/ml.
Emergency room serum NGAL levels >150 ng/ml were
highly sensitive for AKI within 72 hours (96%), but spe-
cificity was only 51% [43]. NGAL is known to be
released by activated neutrophils and appears to be
intrinsically elevated in sepsis, which may explain its
limitation as a biomarker specific for SSAKI.
A variable that may complicate delineation of biomar-
kers for SSAKI is that the pathophysiology of SSAKI
may be different from that of ischemic or nephrotoxic
AKI. Although acute tubular necrosis has traditionally
been considered the etiology of AKI in sepsis, no con-
clusive pathologic evidence has demonstrated that this is
true [18]. Animal models of SSAKI demonstrate
increased, rather than decreased, renal blood flow and a
state of hyperdynamic AKI [44]. The mechanisms med-
iating disease progression are multifactorial, and AKI
during sepsis may be a result of acute tubular apoptosis
rather than acute tubular necrosis [18]. Nonhemody-
namic-dependent mechanisms of injury during sepsis,
inflammatory and immunologic, may trigger this
Table 4 Clinical characteristics of the validation cohort
Characteristic No SSAKI
(n = 59)
SSAKI
(n = 11)
Age (years) 2.1 (0.6 to 4.6) 1.4 (0.9 to 8.5)
Males 34 (58) 10 (91)*
Pediatric Risk of Mortality 10 (7 to 117) 25 (10 to 28)*
Deaths
a 2 (3) 2 (19)
With Gram-negative organism 10 (17) 4 (36)
With Gram-positive organism 9 (15) 4 (36)
With negative cultures 40 (68) 3 (27)*
Data presented as median (interquartile range) or number (%). SSAKI (sepsis
associated acute kidney injury) was defined as a persistent >200% increase of
serum creatinine at day seven of hospitalization.
aTwenty-eight-day mortality.
*P <0.05 versus patients without kidney injury.
Table 5 Individual performance calculations of serum
protein levels for predicting SSAKI in the validation
cohort
Performance MMP-8 Elastase-2
Sensitivity 100 (68 to 100) 100 (68 to 100)
Specificity 41 (28 to 50) 49 (36 to 62)
Positive predictive value 24 (13 to 39) 27 (15 to 43)
Negative predictive value 100 (83 to 100) 100 (85 to 100)
Data expressed as percentage (95% confidence intervals). MMP-8, matrix
metalloproteinase-8; SSAKI, septic-shock-associated acute kidney injury.
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decreased the utility of traditional tests based on the
functionality of proximal tubular filtration [45].
Our study demonstrates that microarray-derived gene
expression data can provide a tool for discovery of can-
didate biomarkers for SSAKI. Outside the neonatal
population, we are the first group to attempt to charac-
terize biomarkers specific to SSAKI (and not all-cause
AKI) in children. Our data represent the first 24 hours
of presentation to medical care, a timeframe that can be
considered a therapeutic window for acute intervention.
It is important to note that our patients were restricted
to having septic shock, an exclusion criterion not pre-
viously used in pediatric studies investigating AKI bio-
markers. Additionally, our definition of SSAKI identifies
patients with severe, persistent kidney injury up to day
7. These candidate biomarkers thus identify patients
with resuscitation unresponsive AKI (that is, patients
having high serum creatinine levels at admission who
subsequently did not normalize with standard resuscita-
tion). The expression patterns of the 21 upregulated
gene probes demonstrate excellent sensitivity and good
specificity for SSAKI (Figure 1). The negative predictive
value of nearly 100% carries obvious import to the bed-
side practitioner, but should be tempered by the fact
that the prevalence of AKI in our cohort was relatively
low (31/179, 17%). Individual performance calculations
of two of these gene products, MMP-8 and elastase-2,
demonstrate reasonable sensitivity in the derivation
cohort (Table 3), but even higher sensitivity in the vali-
dation cohort (Table 5). Additionally, in the validation
cohort, the specificity and negative predictive values of
MMP-8 and elastase-2 increased further. Although
MMP-8 and elastase-2 will require further prospective
validation studies for confirmation, the results are a
relevant demonstration that our gene expression metho-
dology can successfully be leveraged against the tremen-
dous heterogeneity in patients with SSAKI.
The biological links between MMP-8, elastase-2, and
SSAKI are unclear at the present time. MMP-8 is a col-
lagen-cleaving endopeptidase, secreted by neutrophils,
involved in extracellular matrix remodeling. MMP-8 is
implicated in the pathogenesis of numerous rheumatolo-
gic diseases and has been demonstrated as a biomarker
for disease processes ranging from odontogenic inflam-
mation, to left ventricular remodeling after myocardial
infarction, to preterm labor [46-48]. We have recently
identified that MMP-8 may be important in the patho-
genesis of septic shock [49], and Hu and colleagues
demonstrated that the use of an MMP-8 inhibitor pro-
tects mice against endotoxic shock [50]. There are no
previous reports of MMP-8 involvement in the progres-
sion of kidney injury. Neutrophil elastase (elastase-2) is
a serine protease secreted by neutrophils in response to
bacterial infection, is a marker of inflammation, and has
been documented as a biomarker of neonatal sepsis
Table 6 Variables predictive of SSAKI in selected major adult trials
Study Criteria SSAKI (%) Variable outcome
PROWESS [39] Pre-infusion log IL-6, APACHE II
score
127/547
(23.2)
Hazard ratio = 1.16 (95% CI = 1.07 to 1.26); P <0.001
Hazard ratio = 1.23 (95% CI = 1.09 to 1.39); P <0.001
NORASEPT II [54] Plasma IL-6 112/537 (20) Not significant
Plasma TNFa Not significant
Soluble TNFa receptor type I Higher in SSAKI; P <0.0001
Soluble TNFa receptor type II Higher in SSAKI; P <0.0001
PICARD [40] Plasma TNFa 34/97 (35) Higher in patients with SSAKI (P = 0.001) than those without
sepsis
Plasma IL-6 Not significant
Hoste and colleagues [55] APACHE II score 30/185 (16.2) APACHE II score higher (P = 0.002)
pH <7.35 OR for developing ARF = 6.25 (95% CI = 1.92 to 20.4); P = 0.002
Serum creatinine >1 mg/dl OR for developing ARF = 7.56 (95% CI = 2.16 to 26.5); P = 0.002
Martensson and colleagues
[56]
Peak serum NGAL 18/45 (40) Not significant in SSAKI vs. septic shock without AKI
Peak urine NGAL Higher in SSAKI than septic shock without AKI (P <0.05)
Shapiro and colleagues [43] Emergency room plasma NGAL 24/661 (3.6) NGAL >150: sensitivity = 96% and specificity = 51%
de Geus and colleagues [42] Serum NGAL 171/632 (27) OR of developing ARF = 1.7
Urine NGAL OR of developing ARF = 1.42
Sepsis OR of developing ARF = 9.15
AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; NGAL, neutrophil gelatinase-associated lipocalin;
NORASEPT, North American Study for the Safety and Efficacy of Murine Monoclonal Antibody to Tumor Necrosis Factor Alpha for the Treatment of Septic Shock;
OR, odds ratio; PICARD, Program to Improve Care in Acute Renal Disease; PROWESS, Prospective Recombinant Activated Protein C Worldwide Evaluation in
Severe Sepsis; SSAKI, sepsis-shock-associated acute kidney injury; TNF, tumor necrosis factor.
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Page 8 of 11[51]. Interestingly, inhibition of neutrophil elastase
reduced progressive renal injury seen in experimental
direct endotoxin-induced AKI [52].
Our study has several limitations. Since in many
cases neither a baseline creatinine nor a height was
available, the definition of SSAKI in our population
was based on a referenced median-for-age creatinine
[34,35]. Importantly, the initial pediatric RIFLE study
also identified AKI in patients based on assumed esti-
mated creatinine clearance when baseline creatinine
levels were unavailable [53]. Second, some of the per-
formance characteristics (negative and positive predic-
tive values) are influenced by the relatively low
prevalence of AKI in our cohort. This is probably sec-
ondary to the stringent ap r i o r idefinition used for
SSAKI. The intentional use of such a definition
allowed us to identify the most severely affected
patients with fluid-unresponsive AKI [22]. Third, the
data for MMP-8 and elastase-2 continue to demon-
strate the relatively low specificity that many candidate
biomarkers carry for SSAKI. Still, when all 21 upregu-
lated gene probes are analyzed using the leave-one-out
procedure, the specificity increases to 80%, a level not
yet seen for SSAKI biomarkers. Fourth, neither MMP-
8 nor elastase-2 has been studied formally in AKI dis-
ease pathogenesis, from sepsis or other causes. Since
MMP-8 and elastase-2 are neutrophil-derived pro-
teases, it is tempting to speculate that they contribute
to neutrophil tissue invasion and end-organ damage.
In support of such speculation, our microarray data
indicate that septic shock is associated with increased
expression of several basement membrane-related
genes (for example, laminin-family genes) that contri-
bute to neutrophil diapedesis. Finally, our approach
relies on extrapolation of mRNA expression data for
the derivation of serum protein-based biomarkers. This
can be problematic in that mRNA expression does not
always correlate with protein expression. What will be
required in the future is exploration into the feasibility
of measuring the other candidate biomarkers, such as
IFNa-inducible protein 27, which demonstrated a
more than twofold mRNA expression level between
patients with and without SSAKI.
Conclusions
In summary, we present a genomic-based methodology
that can be used to identify novel candidate biomarkers
for SSAKI. Additional validation studies and multicenter
studies are required to investigate the potential of
SSAKI biomarkers identified by gene array.
Key messages
￿ We have used a microarray-based gene expression
database to derive a panel of candidate biomarkers
for early detection of SSAKI in critically ill children
with septic shock.
￿ The expression patterns of 21 gene probes were
able to predict the development of SSAKI with a
high degree of sensitivity and specificity.
￿ The serum protein levels corresponding to two of
these gene probes (MMP-8 and neutrophil elastase-
2) were able to predict SSAKI with a high degree of
sensitivity and a high negative predictive value in
both a derivation cohort and a validation cohort.
￿ The identified candidate genes could provide a
foundation to robustly predict SSAKI.
Additional material
Additional file 1: Gene probes differentially regulated between
patients with and without acute kidney injury. Additional File 1 is a
table listing the gene probes identified from mRNA of patient whole
blood samples that are differentially regulated (up or down) in patients
with acute kidney injury versus those without kidney injury.
Abbreviations
AKI: acute kidney injury; CI: confidence interval; IFN: interferon; IL: interleukin;
MMP-8: matrix metalloproteinase-8; NGAL: neutrophil gelatinase-associated
lipocalin; PICU: pediatric intensive care unit; RIFLE: Risk: Injury: Failure: Loss:
End-Stage kidney injury; ROC: receiver operating characteristic; SSAKI: septic-
shock-associated acute kidney injury.
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